May 29, 2015
To: submissions@nccn.org
Re: Submission Request - Prostate Cancer

Submitted by:
Name: Phillip Febbo, M.D.
Phone – 650 569 2904
Company: Genomic Health Inc.
Address: 301 Penobscot Drive, Redwood City, CA 94063
Date of Request - May 1, 2015
NCCN Guidelines Panel: Prostate Cancer-June 2015

On behalf of Genomic Health Inc., I respectfully request the NCCN Prostate Panel review the enclosed data and include the OncoType DX Prostate Cancer Assay in the guidelines as a diagnostic that provides an independent assessment of the presence of aggressive prostate cancer for men with very low, low, and intermediate risk prostate cancer. The OncoType DX Prostate Cancer Assay has multiple peer-reviewed publications reporting analytic validation, clinical validation, and clinical utility. In patients considering active surveillance, use of the OncoType DX Prostate Cancer Assay provides a precise and more accurate risk estimation that helps inform discussions and decisions between immediate definitive treatment or active surveillance.

Specific change: In the NCCN Guidelines Version 1.2015, tumor-based molecular assays are included as a class in footnote “b” on page PROS-1. The OncoType DX Prostate Cancer Assay is discussed in the supporting text on page MS-4. We recommend the following changes:

1) Include OncoType DX Prostate Cancer Assay as “a 17-gene RT-PCR-based assay to predict adverse pathology” in footnote “b” on page PROS-1 and update the discussion with the second validation study and clinical utility studies in the text on MS-4.

2) Include OncoType DX Prostate Cancer Assay in footnote “f” on page PROS-2 and PROS-3 as “Use of a 17-gene RT-PCR assay to predict adverse pathology can be considered to assess biological risk and guide management in patients with >10 years of life expectancy”.

3) Include OncoType DX Prostate Cancer Assay as the second bullet point on page PROS-C in the section “Principles of Active Surveillance and Observation” as

- Use of a 17-gene RT-PCR assay can assess biological risk and refine risk assessment for men considering active surveillance.

FDA Clearance: Performance of the OncoType DX Prostate Cancer Assay is regulated and certified as a laboratory developed test under the Clinical Laboratory Improvement Amendments (CLIA) and the College of American Pathologists (CAP). FDA clearance is not required for this assay.

Rationale: The robust development of the OncoType DX Prostate Cancer Assay now includes two independent validation studies and two clinical utility studies that demonstrate the test is a strong predictor of aggressive prostate cancer and, most recently, the Palmetto GBA’s MolDX program has reviewed the development plan and issued a positive draft Local Coverage Decision that, when finalized, will provide coverage for Medicare beneficiaries.
The following articles are submitted in support of this proposed change.

**Analytical validation studies**

**Clinical validation studies**

**Clinical utility studies**

Sincerely,

Phil Febbo, MD

**Additional Information:**